Cargando…

miR-34b inhibits nasopharyngeal carcinoma cell proliferation by targeting ubiquitin-specific peptidase 22

OBJECTIVES: This study aimed to investigate the precise role of miR-34b in nasopharyngeal carcinoma (NPC). MATERIALS AND METHODS: The expression of miR-34b and transcription of ubiquitin-specific peptidase 22 (USP22) were examined using quantitative reverse transcription-polymerase chain reaction. W...

Descripción completa

Detalles Bibliográficos
Autores principales: Xiao, Jianyong, Li, Yingying, Zhang, Wenyin, Jiang, Yanni, Du, Biaoyan, Tan, Yuhui
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4803272/
https://www.ncbi.nlm.nih.gov/pubmed/27051294
http://dx.doi.org/10.2147/OTT.S98378
_version_ 1782422859417649152
author Xiao, Jianyong
Li, Yingying
Zhang, Wenyin
Jiang, Yanni
Du, Biaoyan
Tan, Yuhui
author_facet Xiao, Jianyong
Li, Yingying
Zhang, Wenyin
Jiang, Yanni
Du, Biaoyan
Tan, Yuhui
author_sort Xiao, Jianyong
collection PubMed
description OBJECTIVES: This study aimed to investigate the precise role of miR-34b in nasopharyngeal carcinoma (NPC). MATERIALS AND METHODS: The expression of miR-34b and transcription of ubiquitin-specific peptidase 22 (USP22) were examined using quantitative reverse transcription-polymerase chain reaction. Western blot analysis was used to measure the protein expression of USP22. A dualluciferase assay was used to investigate the interaction between miR-34b and USP22. Cell viability was determined by 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide assay. The cell cycle was analyzed by propidium iodide staining followed by flow cytometry analysis. RESULTS: miR-34b was significantly downregulated in NPC tissues and NPC cell lines. Overexpression of miR-34b in NPC SUNE-6-10B cells inhibited cell viability and proliferation. USP22 was highly expressed in NPC cells and promoted cell viability and proliferation. Restoration of USP22 expression could reverse the effect of miR-34b on NPC cell viability and proliferation. CONCLUSION: miR-34b acts as a tumor suppressor in NPC, which is mediated via repression of the oncogene USP22.
format Online
Article
Text
id pubmed-4803272
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-48032722016-04-05 miR-34b inhibits nasopharyngeal carcinoma cell proliferation by targeting ubiquitin-specific peptidase 22 Xiao, Jianyong Li, Yingying Zhang, Wenyin Jiang, Yanni Du, Biaoyan Tan, Yuhui Onco Targets Ther Original Research OBJECTIVES: This study aimed to investigate the precise role of miR-34b in nasopharyngeal carcinoma (NPC). MATERIALS AND METHODS: The expression of miR-34b and transcription of ubiquitin-specific peptidase 22 (USP22) were examined using quantitative reverse transcription-polymerase chain reaction. Western blot analysis was used to measure the protein expression of USP22. A dualluciferase assay was used to investigate the interaction between miR-34b and USP22. Cell viability was determined by 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide assay. The cell cycle was analyzed by propidium iodide staining followed by flow cytometry analysis. RESULTS: miR-34b was significantly downregulated in NPC tissues and NPC cell lines. Overexpression of miR-34b in NPC SUNE-6-10B cells inhibited cell viability and proliferation. USP22 was highly expressed in NPC cells and promoted cell viability and proliferation. Restoration of USP22 expression could reverse the effect of miR-34b on NPC cell viability and proliferation. CONCLUSION: miR-34b acts as a tumor suppressor in NPC, which is mediated via repression of the oncogene USP22. Dove Medical Press 2016-03-16 /pmc/articles/PMC4803272/ /pubmed/27051294 http://dx.doi.org/10.2147/OTT.S98378 Text en 2016 Xiao et al. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
spellingShingle Original Research
Xiao, Jianyong
Li, Yingying
Zhang, Wenyin
Jiang, Yanni
Du, Biaoyan
Tan, Yuhui
miR-34b inhibits nasopharyngeal carcinoma cell proliferation by targeting ubiquitin-specific peptidase 22
title miR-34b inhibits nasopharyngeal carcinoma cell proliferation by targeting ubiquitin-specific peptidase 22
title_full miR-34b inhibits nasopharyngeal carcinoma cell proliferation by targeting ubiquitin-specific peptidase 22
title_fullStr miR-34b inhibits nasopharyngeal carcinoma cell proliferation by targeting ubiquitin-specific peptidase 22
title_full_unstemmed miR-34b inhibits nasopharyngeal carcinoma cell proliferation by targeting ubiquitin-specific peptidase 22
title_short miR-34b inhibits nasopharyngeal carcinoma cell proliferation by targeting ubiquitin-specific peptidase 22
title_sort mir-34b inhibits nasopharyngeal carcinoma cell proliferation by targeting ubiquitin-specific peptidase 22
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4803272/
https://www.ncbi.nlm.nih.gov/pubmed/27051294
http://dx.doi.org/10.2147/OTT.S98378
work_keys_str_mv AT xiaojianyong mir34binhibitsnasopharyngealcarcinomacellproliferationbytargetingubiquitinspecificpeptidase22
AT liyingying mir34binhibitsnasopharyngealcarcinomacellproliferationbytargetingubiquitinspecificpeptidase22
AT zhangwenyin mir34binhibitsnasopharyngealcarcinomacellproliferationbytargetingubiquitinspecificpeptidase22
AT jiangyanni mir34binhibitsnasopharyngealcarcinomacellproliferationbytargetingubiquitinspecificpeptidase22
AT dubiaoyan mir34binhibitsnasopharyngealcarcinomacellproliferationbytargetingubiquitinspecificpeptidase22
AT tanyuhui mir34binhibitsnasopharyngealcarcinomacellproliferationbytargetingubiquitinspecificpeptidase22